Kodak says there's 'substantial doubt' it can stay in business

Eastman Kodak (KODK) has disclosed "substantial doubt" about its ability to continue as a going concern, as detailed in a recent SEC filing. This concern persists despite the company's plans to utilize pension funds to pay down debt and preferred stock, and efforts to refinance remaining obligations, because these strategies are not considered reliable under U.S. accounting rules due to their dependence on external factors. The announcement led to a significant market reaction, with KODK shares falling 24.71% to $5.12, underscoring the company's persistent financial challenges since emerging from bankruptcy in 2013.

Analysis

Eastman Kodak (KODK) has formally disclosed "substantial doubt" about its ability to continue as a going concern in a recent SEC filing, triggering a 24.71% decline in its stock price to $5.12. The company's proposed remedies, which include using returned pension plan funds to service debt and preferred stock, are deemed unreliable under U.S. accounting rules because their success hinges on factors outside of management's control. This development highlights the persistent financial fragility that has plagued the company since it emerged from its 2012 bankruptcy. Despite strategic pivots away from consumer photography towards commercial printing and technology, along with brand licensing efforts, Kodak continues to struggle with its core business viability. The filing underscores a critical juncture for the company, where its historical failure to adapt to technological shifts continues to manifest as severe financial distress, even as it has secured a separate $765M government loan for pharmaceutical production.

Key Decisions for Investors

• Investors should treat the official "substantial doubt" disclosure as a significant red flag, indicating a heightened risk of insolvency and potential for further capital depreciation.
• The stock is now a highly speculative instrument, where any potential upside from its government loan for drug manufacturing is weighed against the severe, stated risk of business failure.
• Monitor subsequent SEC filings closely for any definitive progress on refinancing debt and preferred stock, as the success or failure of these specific actions is critical to the company's short-term survival.